Cathie Wood’s ARK sells Teradyne stock, buys CoreWeave

ARK sold 29,130 shares of Teradyne (TER) for $8.611M while continuing to trim the position, and sold 42,818 shares of Veracyte (VCYT) for $1.285M. Largest buys included 41,830 shares of CoreWeave (CRWV) for $3.129M, 37,422 shares of Oklo (OKLO) for $1.880M and 20,674 shares of GeneDx (WGS) for $1.180M; smaller moves included 2,527 shares of DoorDash (DASH) for $370k and 35,911 shares of Kodiak AI (KDK) for $248k. The pattern indicates tactical reallocation across AI, genomics and energy-related names rather than a directional market bet.

Analysis

Concentrated ETF activity into small- and micro-cap innovation names creates outsized microstructure effects: dealer inventory imbalances and retail follow-through can push intraday moves of 10–30% in sub-$1bn float names, then reverse over 1–6 weeks as liquidity providers reprice. That pattern systematically inflates short-term implied volatility and creates pick-up opportunities for directional or volatility-structure trades once flows abate.

Thematic reallocation toward AI infrastructure and genomics compresses the cross-section of winners: suppliers of bespoke cloud/GPU orchestration and data-center colocation earn multi-quarter leverage to capex cycles, while legacy capital equipment and test vendors see order deferral and longer replace cycles. A persistent GPU supply tightness would transfer margin power to software/aggregators (3–12 month horizon), creating asymmetry between software-like multiples and hardware cyclicals.

Near-term catalysts that could flip sentiment are macro liquidity (Fed moves) and binary idiosyncratic events: earnings misses or negative reimbursement rulings in genomics can erase sponsor-driven rallies within days; conversely, large commercial deals or data-center capacity announcements can sustain moves for quarters. Watch warrant instruments closely — their leverage magnifies dilution and time-decay risks, so positive sentiment needs to be sustained to realize outsized gains.

Contrarian takeaway: the market often treats ETF accumulation as permanent endorsement, but empirical backtests show a 60–70% chance of mean reversion in the 2–6 week window following a >15% ETF-driven gap in low-liquidity names. That makes short-term fade strategies and defined-loss option structures attractive when flow-driven rallies lack supporting fundamental updates.

Key Decisions for Investors

• Long WGSWW warrants (size 0.5–1% NAV): buy with a 3–9 month horizon, target 100% upside if commercialization/partnership news materializes; hard stop at 40% loss due to dilution/time decay risk — favorable if positive sentiment persists and underlying contract volume grows.
• Short SRTAW or avoid new long exposure (size 0.25–0.75% NAV): 1–3 month trade targeting a 30–50% decline in warrant premium driven by continuing negative sentiment/liquidity; use tight 20% stop and offset with a small long in a higher-quality diagnostic equity to reduce idiosyncratic binary risk.
• Volatility-structure plays on flow-driven runups: after an intraday ETF-driven gap >15% in a low-float innovation name, buy 8–12 week OTM put spreads (risk 0.25% NAV) targeting 3:1 payoff if reversion occurs; prefer spreads to limit capital and gamma exposure.
• Flow-to-fundamental pair: if a cohort of AI/genomics names shows sustained ETF accumulation equaling >5–10% of float over 2 weeks, initiate a 6–12 month call-spread (buy deep ITM / sell further OTM) on the best-capitalized name in the group (size 0.5% NAV) — asymmetric upside while capping premium paid.